• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-08-03

  Xue et al. provide the first direct evidence that male and female mice display markedly different hypertensive responses to chronic angiotensin II (ANG II) infusion. Their findings clarify how sex hormones and autonomic regulation shape these outcomes, emphasizing the importance of considering sex as a biological variable in hypertension and cardiovascular research.

• CIP2A Promotes PKM2 Tetramerization and OXPHOS in NSCLC Meta

  2026-08-03

  This study demonstrates that CIP2A, an oncogenic regulator, promotes oxidative phosphorylation in non-small cell lung cancer by inducing PKM2 tetramerization and mitochondrial localization. These findings challenge the traditional Warburg-centric view of cancer metabolism and suggest new therapeutic strategies targeting CIP2A and glycolysis in NSCLC.

• M1 Macrophage Exosomes Drive Enteric Neuronal Injury via MMP

  2026-08-02

  This study uncovers a critical neuroimmune mechanism in which M1 macrophage-derived exosomes enriched in MMP8 induce enteric neuronal apoptosis through TGF-β pathway activation, contributing to gastrointestinal motility disorders. The findings highlight MMP8 as a potential therapeutic target and provide mechanistic insights relevant for researchers studying neuroimmune regulation of gut motility.

• Boc-D-FMK: Pan-Caspase Inhibitor for Apoptosis & Inflammatio

  2026-08-01

  Boc-D-FMK is a cell-permeable, irreversible pan-caspase inhibitor used to block apoptotic and inflammatory signaling in vitro and in vivo. Its robust inhibition of caspase activity and downstream TNF-α pathways makes it a standard tool in apoptosis research. Evidence-based protocols ensure reproducible outcomes in renal endothelial and hepatocyte apoptosis models.

• Belinostat (PXD101): Protocol-Driven Advances in Cancer Rese

  2026-07-31

  Belinostat (PXD101) stands out as a potent pan-HDAC inhibitor, enabling precise epigenetic modulation in in vitro cancer models. This article delivers actionable protocols, troubleshooting strategies, and evidence-backed workflow enhancements to maximize assay reproducibility and insight, especially in bladder and prostate cancer research.

• TREM2 Controls Microglial Activation via ERK/p38 in Autoimmu

  2026-07-31

  This study identifies TREM2 as a regulator of microglial activation and inflammation in experimental autoimmune uveitis by modulating the ERK/p38 MAPK pathway. The findings offer mechanistic insight into retinal immune responses and highlight TREM2 as a potential therapeutic target for non-infectious uveitis.

• Dovitinib (TKI-258): Targeting Tumor Hypoxia and Immunometab

  2026-07-30

  Explore how Dovitinib (TKI-258) reshapes cancer research by intersecting RTK inhibition with hypoxia-driven immunometabolic pathways. This in-depth analysis delivers unique insights into experimental design, apoptosis induction in cancer cells, and the evolving landscape of tumor-targeted therapies.

• Applied Use of CNQX for Targeted Glutamatergic Inhibition

  2026-07-30

  CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) enables precise blockade of AMPA and kainate receptors, making it an indispensable tool for dissecting non-NMDA glutamatergic signaling in central nervous system research. This guide distills advanced experimental workflows, real-world troubleshooting, and application-driven insights grounded in recent cardiovascular-neuroscience breakthroughs.

• Applied Workflows for Amyloid Beta-peptide (25-35) Neurotoxi

  2026-07-29

  Amyloid Beta-peptide (25-35) (Aβ25-35) is the gold standard for modeling Alzheimer’s neurotoxicity, enabling precise dissection of microglial activation and amyloid-induced cell death. This guide reveals optimized workflows, troubleshooting strategies, and translational insights, leveraging APExBIO’s rigorously validated peptide for reproducible, high-impact research.

• Fluorouracil (Adrucil): Molecular Mechanisms and Emerging Fr

  2026-07-29

  Explore the molecular precision of Fluorouracil (5-Fluorouracil, Adrucil) in solid tumor research, its unique DNA/RNA mimicry, and how new insights into the Wnt pathway influence future assay design. This article delivers a deep scientific perspective for oncology researchers.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Protocol and QC Gui

  2026-07-28

  The FITC Goat Anti-Mouse IgG (H+L) Antibody facilitates specific and sensitive detection of mouse IgG in immunoassays where fluorescent signal amplification is required. It is best suited for workflows such as immunofluorescence and flow cytometry with mouse primary antibodies, but is not appropriate for direct detection of non-mouse or non-IgG targets, nor for applications sensitive to sodium azide.

• Capsaicin (E)-Capsaicin: Advanced Workflows for TRPV1 Resear

  2026-07-28

  Capsaicin (E)-Capsaicin empowers researchers to dissect TRPV1 ion channel activation and KDM1A/LSD1 inhibition in pain, inflammation, and cancer models. Recent findings on chronic dermatitis reveal new mechanistic insights, while APExBIO’s validated reagent supports reproducible, high-impact experimental workflows.

• SB743921 (SKU B1590): Precision KSP Inhibition in Cancer Res

  2026-07-27

  This article delivers scenario-driven guidance for researchers using SB743921 (SKU B1590), a potent and selective kinesin spindle protein inhibitor, to address common experimental challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed evidence and recent protocol advances, we demonstrate how SB743921 provides reliable and reproducible solutions in cancer research workflows.

• MDM1 Overexpression Enhances Chemoradiotherapy Sensitivity v

  2026-07-27

  This article reviews recent evidence showing that MDM1 overexpression increases p53 expression and cancer cell apoptosis, enhancing the therapeutic sensitivity of colorectal cancer to chemoradiotherapy. These findings highlight MDM1 as a potential predictive biomarker and open avenues for leveraging p53 pathway modulators in precision oncology.

• Sunitinib: Mechanistic Precision and Next-Gen Synergy in RCC

  2026-07-26

  Explore the advanced mechanism of Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, with a unique focus on recent breakthroughs in overcoming resistance in renal cell carcinoma research. This article delivers deep scientific insight and practical guidance for experimental design.

449 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page